Revolution Medicines, Inc. Research and Development Expense
Revolution Medicines, Inc. (RVMD) reported Research and Development Expense of $394.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Revolution Medicines, Inc. research and development expense for the quarter ending 2026-06-30 was $394.92M, a 76.20% increase year-over-year.
- Revolution Medicines, Inc. research and development expense for the quarter ending 2026-03-31 was $343.97M, a 67.18% increase year-over-year.
- Revolution Medicines, Inc. research and development expense for the quarter ending 2025-12-31 was $294.94M, a 56.80% increase year-over-year.
- Revolution Medicines, Inc. research and development expense for the quarter ending 2025-09-30 was $262.51M, a 72.98% increase year-over-year.
- Revolution Medicines, Inc. research and development expense for fiscal 2025 was $987.33M, a 66.72% increase from fiscal 2024.
- Revolution Medicines, Inc. research and development expense for fiscal 2024 was $592.23M, a 39.96% increase from fiscal 2023.
- Revolution Medicines, Inc. research and development expense for fiscal 2023 was $423.14M, a 67.20% increase from fiscal 2022.
- Revolution Medicines, Inc. research and development expense for fiscal 2022 was $253.07M, a 35.37% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $394.92M 10-Q · filed 2026-08-05 | $738.89M 10-Q · filed 2026-08-05 | $1.03B derived: sum of 3 quarters · filed 2026-08-05 | $1.30B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $343.97M 10-Q · filed 2026-05-06 | $638.91M derived: sum of 2 quarters · filed 2026-05-06 | $901.42M derived: sum of 3 quarters · filed 2026-05-06 | $1.13B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $294.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $557.45M derived: sum of 2 quarters · filed 2026-02-25 | $781.58M derived: sum of 3 quarters · filed 2026-08-05 | $987.33M 10-K · filed 2026-02-25 |
| 2025-09-30 | $262.51M 10-Q · filed 2025-11-05 | $486.64M derived: sum of 2 quarters · filed 2026-08-05 | $692.39M 10-Q · filed 2025-11-05 | $880.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $224.13M 10-Q · filed 2026-08-05 | $429.88M 10-Q · filed 2026-08-05 | $617.98M derived: sum of 3 quarters · filed 2026-08-05 | $769.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $205.75M 10-Q · filed 2026-05-06 | $393.85M derived: sum of 2 quarters · filed 2026-05-06 | $545.60M derived: sum of 3 quarters · filed 2026-05-06 | $680.53M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $188.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $339.85M derived: sum of 2 quarters · filed 2026-02-25 | $474.78M derived: sum of 3 quarters · filed 2026-02-25 | $592.23M 10-K · filed 2026-02-25 |
| 2024-09-30 | $151.75M 10-Q · filed 2025-11-05 | $286.68M derived: sum of 2 quarters · filed 2025-11-05 | $404.13M 10-Q · filed 2025-11-05 | $553.19M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $134.93M 10-Q · filed 2025-08-06 | $252.95M 10-Q · filed 2025-08-06 | $401.43M derived: sum of 3 quarters · filed 2026-02-25 | $509.17M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $118.02M 10-Q · filed 2025-05-07 | $266.50M derived: sum of 2 quarters · filed 2026-02-25 | $374.24M derived: sum of 3 quarters · filed 2026-02-25 | $472.22M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $148.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $256.22M derived: sum of 2 quarters · filed 2026-02-25 | $354.20M derived: sum of 3 quarters · filed 2026-02-25 | $423.14M 10-K · filed 2026-02-25 |
| 2023-09-30 | $107.73M 10-Q · filed 2024-11-06 | $205.72M derived: sum of 2 quarters · filed 2024-11-06 | $274.66M 10-Q · filed 2024-11-06 | $340.79M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $97.98M 10-Q · filed 2024-08-07 | $166.93M 10-Q · filed 2024-08-07 | $233.06M derived: sum of 3 quarters · filed 2025-02-26 | $302.51M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $68.95M 10-Q · filed 2024-05-08 | $135.07M derived: sum of 2 quarters · filed 2025-02-26 | $204.53M derived: sum of 3 quarters · filed 2025-02-26 | $265.53M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $66.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $135.58M derived: sum of 2 quarters · filed 2025-02-26 | $196.58M derived: sum of 3 quarters · filed 2025-02-26 | $253.07M 10-K · filed 2025-02-26 |
| 2022-09-30 | $69.45M 10-Q · filed 2023-11-06 | $130.46M derived: sum of 2 quarters · filed 2023-11-06 | $186.95M 10-Q · filed 2023-11-06 | $240.63M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $61.00M 10-Q · filed 2023-08-08 | $117.49M 10-Q · filed 2023-08-08 | $171.17M derived: sum of 3 quarters · filed 2024-02-26 | $217.65M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $56.49M 10-Q · filed 2023-05-08 | $110.17M derived: sum of 2 quarters · filed 2024-02-26 | $156.64M derived: sum of 3 quarters · filed 2024-02-26 | $202.58M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $53.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $100.15M derived: sum of 2 quarters · filed 2024-02-26 | $146.09M derived: sum of 3 quarters · filed 2024-02-26 | $186.95M 10-K · filed 2024-02-26 |
| 2021-09-30 | $46.47M 10-Q · filed 2022-11-07 | $92.41M derived: sum of 2 quarters · filed 2022-11-07 | $133.27M 10-Q · filed 2022-11-07 | $170.27M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $45.94M 10-Q · filed 2022-08-09 | $86.79M 10-Q · filed 2022-08-09 | $123.80M derived: sum of 3 quarters · filed 2023-02-27 | $158.67M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $40.86M 10-Q · filed 2022-05-09 | $77.86M derived: sum of 2 quarters · filed 2023-02-27 | $112.73M derived: sum of 3 quarters · filed 2023-02-27 | $145.65M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $37.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $71.88M derived: sum of 2 quarters · filed 2023-02-27 | $104.80M derived: sum of 3 quarters · filed 2023-02-27 | $132.25M 10-K · filed 2023-02-27 |
| 2020-09-30 | $34.87M 10-Q · filed 2021-11-10 | $67.79M derived: sum of 2 quarters · filed 2021-11-10 | $95.25M 10-Q · filed 2021-11-10 | $122.74M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $32.92M 10-Q · filed 2021-08-11 | $60.38M 10-Q · filed 2021-08-11 | $87.86M derived: sum of 3 quarters · filed 2022-02-28 | $110.83M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $27.46M 10-Q · filed 2021-05-10 | $54.95M derived: sum of 2 quarters · filed 2022-02-28 | $77.91M derived: sum of 3 quarters · filed 2022-02-28 | $98.03M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $27.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $50.45M derived: sum of 2 quarters · filed 2022-02-28 | $70.57M derived: sum of 3 quarters · filed 2022-02-28 | $91.75M 10-K · filed 2022-02-28 |
| 2019-09-30 | $22.96M 10-Q · filed 2020-11-12 | $43.08M derived: sum of 2 quarters · filed 2020-11-12 | $64.27M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $20.12M 10-Q · filed 2020-08-10 | $41.30M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $21.19M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $51.08M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |